IPO - Profile

Day One Biopharmaceuticals Holding Company, LLC

Health Care > Biotechnology: Biological Products (No Diagnostic Substances)

DAWN

Summary

Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Our name was inspired by the “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. We aim to re-envision cancer drug development and redefine what’s possible for all people living with cancer–regardless of age–starting from Day One.

We are a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$16.00 10,000,000 Positive High 19.6%

Offering Team

  • Legal counsel
  • Fenwick & West LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 26 May, 2021

Offer 27 May, 2021

Look Ahead

Lock Up Expiry Nov 27, 2021

IPO Terms

Offer Price $16.00
Offer Size 10M

Market Sentiments

Stock Price